GSK, XenoPort terminate extended-release gabapentin deal – FierceDrugDelivery

by admin on November 13, 2012

GSK, XenoPort terminate extended-release gabapentin deal
FierceDrugDelivery
GSK had commercialization and development rights in the U.S., where the drug was approved for the treatment of restless legs syndrome in April 2011, and for post-shingles pain in June 2012. All of these rights are being returned to XenoPort. XenoPort

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: